A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Hepatocellular Carcinoma
Interventions: DRUG: eFT508
Sponsor: Effector Therapeutics